Envestnet Asset Management Inc. lessened its stake in shares of Novartis AG (NYSE:NVS - Free Report) by 0.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,938,731 shares of the company's stock after selling 14,966 shares during the period. Envestnet Asset Management Inc. owned 0.09% of Novartis worth $188,658,000 as of its most recent SEC filing.
Other institutional investors also recently modified their holdings of the company. IHT Wealth Management LLC raised its holdings in Novartis by 44.9% in the 3rd quarter. IHT Wealth Management LLC now owns 3,216 shares of the company's stock worth $369,000 after acquiring an additional 996 shares during the period. Stifel Financial Corp increased its stake in shares of Novartis by 3.9% in the third quarter. Stifel Financial Corp now owns 219,027 shares of the company's stock worth $25,194,000 after purchasing an additional 8,284 shares during the period. EP Wealth Advisors LLC lifted its position in shares of Novartis by 15.6% during the 3rd quarter. EP Wealth Advisors LLC now owns 13,630 shares of the company's stock worth $1,568,000 after purchasing an additional 1,837 shares during the last quarter. Orion Portfolio Solutions LLC boosted its stake in Novartis by 3.4% during the 3rd quarter. Orion Portfolio Solutions LLC now owns 32,423 shares of the company's stock valued at $3,729,000 after purchasing an additional 1,079 shares during the period. Finally, Dorsey Wright & Associates acquired a new stake in Novartis in the 3rd quarter valued at approximately $2,371,000. Institutional investors own 13.12% of the company's stock.
Novartis Price Performance
Shares of NYSE:NVS traded up $4.14 during midday trading on Friday, reaching $107.54. 4,745,829 shares of the company's stock were exchanged, compared to its average volume of 1,555,257. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.84 and a current ratio of 1.04. The company's 50 day simple moving average is $108.96 and its two-hundred day simple moving average is $106.44. Novartis AG has a 12 month low of $92.35 and a 12 month high of $120.92. The firm has a market capitalization of $219.82 billion, a PE ratio of 18.29, a price-to-earnings-growth ratio of 1.70 and a beta of 0.56.
Novartis (NYSE:NVS - Get Free Report) last announced its quarterly earnings results on Friday, January 31st. The company reported $1.98 EPS for the quarter, topping analysts' consensus estimates of $1.80 by $0.18. Novartis had a net margin of 23.56% and a return on equity of 37.24%. Equities research analysts expect that Novartis AG will post 8.45 earnings per share for the current fiscal year.
Novartis Announces Dividend
The business also recently declared a dividend, which was paid on Wednesday, March 12th. Investors of record on Wednesday, March 12th were paid a $3.8695 dividend. The ex-dividend date was Wednesday, March 12th. Novartis's dividend payout ratio is 42.69%.
Analyst Upgrades and Downgrades
A number of brokerages have recently commented on NVS. Deutsche Bank Aktiengesellschaft upgraded Novartis from a "hold" rating to a "buy" rating in a report on Tuesday, February 4th. Barclays reiterated an "underweight" rating on shares of Novartis in a research note on Monday, February 3rd. StockNews.com upgraded shares of Novartis from a "buy" rating to a "strong-buy" rating in a research report on Saturday, February 8th. Morgan Stanley initiated coverage on shares of Novartis in a report on Wednesday, February 12th. They set an "underweight" rating on the stock. Finally, UBS Group reiterated a "neutral" rating on shares of Novartis in a research note on Thursday, February 13th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $123.38.
Check Out Our Latest Research Report on NVS
Novartis Profile
(
Free Report)
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
Further Reading
Before you consider Novartis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novartis wasn't on the list.
While Novartis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
